You are required to be logged in to access the full website
User Name: Password:
Click here if you have forgotten your username or password
  • Home
  • Latest News
  • Search
  • About M2 Pharma
  • Subscribe
Business & Finance
Generics
Therapy Areas
Policy & Regulation
Research & Development
People
Policy & Regulation
HUTCHMED receives full NMPA approval for ORPATHYS in China for MET exon 14 skipping NSCLC
Login
Username:

Password:


Related Headlines

Avetra unveils site-centric CRO operating model

Spinogenix reports approval of 'tazbentetol' as non-proprietary name for SPG302

Xeris Biopharma receives USPTO Notice of Allowance for XP-8121 patent

Ionis Pharmaceuticals granted FDA Breakthrough Therapy Designation for olezarsen in severe hypertriglyceridemia

Polarean expands XENOVIEW 3T Coil access with Philips compatibility

Avandra Health acquires DatCard Systems and Sorna Corporation

Zentiva receives ESG Transparency Award 2025

Immedica gets UAE approval for Zepzelca maintenance treatment

Imugene Ltd enters co-development collaboration with JW Therapeutics (Shanghai)

Sichuan Kelun-Biotech's TROP2 ADC sacituzumab tirumotecan (sac-TMT) monotherapy clinical study results published in Annals of Oncology

Kedrion's investigational treatment for Congenital Aceruloplasminemia receives European Orphan Drug Designation

Workit Health Reopens Services in California, Expanding Statewide Access to Virtual Opioid and Alcohol Treatment

Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide

Mendus reports trial follow-up data supporting potential of vididencel in high-risk ovarian cancer

Novo Nordisk submits sNDA to FDA for for higher semaglutide injection dose

Home | Business & Finance | Generics | Therapy Areas | Policy & Regulation | Research & Development | People | Search | About M2 Pharma | Subscribe
Copyright © 2025